In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University of Alberta

www.ualberta.ca

Latest From University of Alberta

Life Science Start-Ups: Tech Transfer Deals, July-August 2014

Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June 2014.

BioPharmaceutical Medical Device

Life Science Start-Ups: Tech Transfer Deals, May 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2014.

BioPharmaceutical Medical Device

Device/Diagnostics Quarterly Deal Statistics, Q3 2012

Device companies raised a total of $801 million in 2012’s third quarter, an 18% drop from Q2’s $977 million. Approximately $2.6 billion was spent on device acquisitions, exactly $2 billion less than Q2’s total. Diagnostic/research company financings totaled $484 million during Q3 2012, up from last quarter’s $336 million. And while diagnostic/research M&A activity was not as prolific as last quarter, tech transfer deals are seeing a resurgence.

Medical Device Deals

Fedora Pharmaceuticals Inc.

In recent decades, both gram-positive and gram-negative bacteria previously susceptible to beta-lactam antibiotics have developed enzymes that render them inactive. Fedora Pharmaceuticals Inc. believes it has identified compounds that may prove able to thwart all four classes of beta-lactamases. Its compounds are meant to be used in combination with existing beta-lactam antibiotics that were historically effective but are no longer.

BioPharmaceutical
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register